MedTrace Logo

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

NCT05429632 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 366

Last updated 2026-05-14

No results posted yet for this study

Summary

This is a multi-center, randomized, double-blinded, placebo controlled trial.

Conditions

  • Adult Acute Myeloid Leukemia

Interventions

DRUG

mocravimod

S1PR modulator

Sponsors & Collaborators

  • Priothera SAS

    lead INDUSTRY

Principal Investigators

  • Marcos DeLima, MD · The Ohio State University Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-16
Primary Completion
2027-05-31
Completion
2029-11-30
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • France
  • Germany
  • Israel
  • Italy
  • Japan
  • Poland
  • Romania
  • Spain
  • Switzerland
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05429632 on ClinicalTrials.gov